Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety and efficacy of Keverprazan for reflux esophagitis in China
ChiCTR2400089974Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of keverprazan in erosive esophagitis (EE), sponsored by Renji Hospital. Primary endpoint: Percentage of participants with adverse events post-Keverprazan treatment. Started Apr 2025; status: recruiting.
02
Drugs
keverprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on ChiCTR2400089974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089974.